We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $20B
1-Year Est. Return 154.41%
This Fund
S&P 500
This Quarter Est. Return
+3.33%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$7.83B
AUM Growth
-$147M
Cap. Flow
+$37.6M
Cap. Flow %
0.48%
Top 10 Hldgs %
76.26%
Holding
100
New
11
Increased
18
Reduced
11
Closed
5

Top Buys

Rank Stock Value
1
SMMT icon
Summit Therapeutics
SMMT
+$125M
2
INSM icon
Insmed
INSM
+$125M
3
ALKS icon
Alkermes
ALKS
+$103M
4
BCYC
Bicycle Therapeutics
BCYC
+$101M
5
ALMS
Alumis Inc
ALMS
+$20.8M

Top Sells

Rank Stock Value
1
INCY icon
Incyte
INCY
+$308M
2
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$55.5M
3
ROIV icon
Roivant Sciences
ROIV
+$50.6M
4
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$38.2M
5
AKRO
Akero Therapeutics
AKRO
+$34.6M

Sector Composition

Rank Sector Weight
1 Healthcare 98.1%
2 Miscellaneous 1.87%
3 Financials 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LONA
51
LeonaBio Inc
LONA
$65.2M
$8.36M 0.11%
315,381
– –
VERV
52
DELISTED
Verve Therapeutics
VERV
$8.25M 0.11%
1,691,530
– –
RLAY icon
53
Relay Therapeutics
RLAY
$4.18B
$7.56M 0.1%
1,160,117
– –
MIRM icon
54
Mirum Pharmaceuticals
MIRM
$6.28B
$6.51M 0.08%
190,476
– –
TNGX icon
55
Tango Therapeutics
TNGX
$4.14B
$6.43M 0.08%
750,000
– –
KALA icon
56
KALA BIO
KALA
$10.5M
$6.32M 0.08%
17,827
+12,495
+234% +$4.13M
DBVT
57
DBV Technologies
DBVT
$745M
$5.85M 0.07%
1,461,426
– –
DSGN icon
58
Design Therapeutics
DSGN
$846M
$5.68M 0.07%
1,695,294
+33,174
+2% +$129K
CTNM
59
Contineum Therapeutics
CTNM
$558M
$5.5M 0.07%
+312,500
New +$5.03M
PRAX icon
60
Praxis Precision Medicines
PRAX
$9.23B
$5.44M 0.07%
131,533
– –
CRSP icon
61
CRISPR Therapeutics
CRSP
$5.12B
$5.4M 0.07%
+100,000
New +$5.78M
PRME icon
62
Prime Medicine
PRME
$577M
$5.29M 0.07%
1,028,466
– –
CNTA
63
DELISTED
Centessa Pharmaceuticals
CNTA
$4.96M 0.06%
+549,212
New +$5.21M
HOOK
64
DELISTED
HOOKIPA Pharma
HOOK
$4.81M 0.06%
812,815
– –
SGMT icon
65
Sagimet Biosciences
SGMT
$676M
$4.73M 0.06%
1,381,898
– –
CRNX
66
DELISTED
Crinetics Pharmaceuticals
CRNX
$4.65M 0.06%
+103,927
New +$4.8M
TLIS
67
DELISTED
Talis Biomedical Corporation Common Stock
TLIS
$4.4M 0.06%
508,323
– –
ALEC icon
68
Alector
ALEC
$239M
$4.21M 0.05%
+927,264
New +$4.77M
OPT
69
DELISTED
Opthea Limited American Depositary Shares
OPT
$4.2M 0.05%
2,173,622
-4,204
-0.2% -$13.3K
SKYE icon
70
Skye Bioscience
SKYE
$9.03M
$4M 0.05%
+62,500
New +$5.93M
PCVX icon
71
Vaxcyte
PCVX
$8.86B
$3.69M 0.05%
48,885
– –
ARCT icon
72
Arcturus Therapeutics
ARCT
$435M
$3.68M 0.05%
+151,329
New +$4.59M
GBIO
73
DELISTED
Generation Bio
GBIO
$3.4M 0.04%
120,696
+83,574
+225% +$2.72M
ELVN icon
74
Enliven Therapeutics
ELVN
$3.99B
$2.68M 0.03%
114,833
– –
CYPH
75
Cypherpunk Technologies Inc
CYPH
$278M
$2.3M 0.03%
1,172,175
– –
1 2
3
4

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Baker Bros. Advisors's Q2 2024 Portfolio in Review

As of Q2 2024, Baker Bros. Advisors held 100 positions worth $7.83B, down 1.8% from $7.97B the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Baker Bros. Advisors's Q2 2024 filing shows 11 new, 18 increased, 11 reduced and 5 closed positions. Its largest new stake was Summit Therapeutics: 23,222,222 shares worth $181M. The largest sale was Incyte, an estimated $308M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 100% a quarter earlier, followed by Miscellaneous and Financials.

  • Baker Bros. Advisors's largest Q2 2024 buy was Summit Therapeutics: 23,222,222 shares worth $181M.
  • Baker Bros. Advisors added most to Insmed in Q2 2024, an estimated $125M increase.
  • Baker Bros. Advisors's biggest Q2 2024 reduction was Incyte, cutting an estimated $308M.
  • Baker Bros. Advisors fully exited Alpine Immune Sciences Inc in Q2 2024, selling an estimated $3.23M.
  • Baker Bros. Advisors's ten largest holdings make up 76% of its $7.83B portfolio in Q2 2024.
  • Baker Bros. Advisors opened 11 new positions and closed 5 in Q2 2024.
  • Baker Bros. Advisors's portfolio value fell 1.8% quarter-over-quarter to $7.83B.

Based on Baker Bros. Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.